SCHEMBL8319331

SCHEMBL8319331

C#Cc1ccc(NC(=O)O)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 1/20 0.50
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
KDM4E B2RXH2 2/20 0.45
RAB9A P51151 2/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
ALDH1A1 P00352 1/20 0.45
HPGD P15428 1/20 0.45
CYP2C19 P33261 1/20 0.45
LMNA P02545 2/20 0.43
MAPT P10636 2/20 0.43
NPC1 O15118 1/20 0.43
CASP3 P42574 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
MAOB P27338 1/20 0.43
GBA1 P04062 1/20 0.43
PTPN11 Q06124 1/20 0.42
TSHR P16473 1/20 0.39
HTT P42858 1/20 0.39
NLRP3 Q96P20 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4748577 0.84 CYP2C9 (0.56) CYP2C9MEN1KMT2AKDM4ERAB9A
SCHEMBL13379288 0.83 PTPN11 (0.61) PTPN11
SCHEMBL3309759 0.82 PTPN11 (0.59) PTPN11
SCHEMBL17424508 0.82 CYP2C9 (0.67) CYP2C9MEN1KMT2AKDM4ERAB9A
SCHEMBL474661 0.81 KMT2A (0.70) MEN1KMT2AKDM4ERAB9ASMN1; SMN2
SCHEMBL4552493 0.81 PEPD (0.57) CYP2C9MEN1KMT2AKDM4ERAB9A
SCHEMBL10778839 0.81 SMN1; SMN2 (0.52) KMT2ARAB9ASMN1; SMN2MAPTNPC1
SCHEMBL13950464 0.80 POLB (0.46) CYP2C9MEN1KMT2ARAB9ASMN1; SMN2
SCHEMBL9771269 0.79 KMT2A (0.68) MEN1KMT2AKDM4ERAB9ASMN1; SMN2
SCHEMBL4312329 0.79 NPC1 (0.57) MEN1KMT2AKDM4ERAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741383-A1 COMPOUND AND USE THEREOF AS ANTI-CANCER DRUG Tyligand Bioscience (Shanghai) Limited (CN) 2026-05-13 EP disclosed
WO-2024083111-A1 NOVEL HETEROCYCLIC COMPOUNDS 首药控股(北京)股份有限公司 2024-04-25 WO disclosed
WO-2024008033-A1 CLASS OF 7-((FIVE-MEMBERED HETEROCYCLIC)METHYL)-8-CARBOXYLIC ACID-BENZO CYCLIC BORATE DERIVATIVES AND USES THEREOF 福安药业集团重庆三禾兴医药科技有限公司 2024-01-11 WO disclosed
EP-3625218-B1 PROCESS FOR HYDROCYANATION OF TERMINAL ALKYNES STUDIENGESELLSCHAFT KOHLE MBH (DE) 2023-03-01 EP disclosed
US-10947186-B2 Process for hydrocyanation of terminal alkynes STUDIENGESELLSCHAFT KOHLE MBH (DE) 2021-03-16 US disclosed
US-20200181068-A1 PROCESS FOR HYDROCYANATION OF TERMINAL ALKYNES STUDIENGESELLSCHAFT KOHLE MBH (DE) 2020-06-11 US disclosed
EP-3625218-A1 PROCESS FOR HYDROCYANATION OF TERMINAL ALKYNES Studiengesellschaft Kohle mbH (DE) 2020-03-25 EP disclosed
WO-2018210631-A1 PROCESS FOR HYDROCYANATION OF TERMINAL ALKYNES STUDIENGESELLSCHAFT KOHLE MBH (DE) 2018-11-22 WO disclosed
EP-3127900-B1 ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF SENJU PHARMA CO (JP) 2017-10-18 EP disclosed
US-9617222-B1 Alkynyl indazole derivative and use thereof SENJU PHARMACEUTICAL CO., LTD. (JP) 2017-04-11 US disclosed
US-20170096400-A1 ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF SENJU PHARMACEUTICAL CO., LTD. (JP) 2017-04-06 US disclosed
EP-3127900-A1 ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF Senju Pharmaceutical Co., Ltd. (JP) 2017-02-08 EP disclosed
US-8748412-B2 Phenylalanine derivatives and their use as non-peptide GLP-1 receptor modulators ARGUSINA BIOSCIENCE INC. (KY) 2014-06-10 US disclosed
EP-2531198-A1 PHENYLALANINE DERIVATIVES AND THEIR USE AS NON-PEPTIDE GLP-1 RECEPTOR MODULATORS Argusina Inc. (US) 2012-12-12 EP disclosed
EP-1597244-B1 ETHYNYL DERIVATIVES SERVING AS FACTOR XA INHIBITORS MERCK PATENT GMBH (DE) 2010-07-07 EP disclosed
WO-2004076429-A1 ETHYNYL DERIVATIVES SERVING AS FACTOR XA INHIBITORS MERCK PATENT GMBH (DE) 2004-09-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200181068-A1 PROCESS FOR HYDROCYANATION OF TERMINAL ALKYNES ALKBH3, ALKBH2, ALKBH5 CYP2C9 978/4885MEN1 2865/4885KMT2A 507/4885
US-10947186-B2 Process for hydrocyanation of terminal alkynes ALKBH3, ALKBH2, ALKBH5 CYP2C9 978/4885MEN1 2865/4885KMT2A 507/4885
US-20170096400-A1 ALKYNYL INDAZOLE DERIVATIVE AND USE THEREOF KDR, FLT1, FLT4 CYP2C9 2973/4885MEN1 4422/4885KMT2A 4546/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.